Gimv invests in the Homecare Apraxon Group
Hofbieber/Munich (DE), Antwerp (BE) — Gimv invests in the Apraxon Group, a leading homecare company focused on wound care in Germany. The transaction, which has already been completed, is part of a joint growth plan with the company’s founder and CEO, Oliver Pokrzewinski, who will continue to be a key shareholder in the company.
Apraxon, (Hofbieber (DE) — apraxon.com), offers high-quality wound care for (mainly elderly) people with chronic wounds in the homecare sector. Typical wound indications are decubitus, diabetic foot or ulcus cruris. In this context, the company acts as a link between patients, doctors, nursing service/home and the health insurance companies.
Due to its high degree of specialization, Apraxon provides a continuously high quality of medical care and is able to tailor the treatment process to the individual needs of each patient. In a market with steadily rising patient numbers, driven primarily by demographic change, specialized medical care is becoming increasingly important. The services are reimbursed by health insurance companies, for which Apraxon has been a reliable partner for many years.
“I am convinced that Gimv is the right partner to realize the company’s growth ambitions and expand Apraxon’s presence in Germany,” said Oliver Pokrzewinski, Managing Director and CEO of Apraxon.
“Thanks to Apraxon’s clear commitment to quality, the above-average qualification of their nursing staff and their highly digitalized and scalable processes, we are convinced that Apraxon is the right platform to build a true market leader in German wound care. We are very much looking forward to supporting Mr. Pokrzewinski and the entire Apraxon team in implementing their ambitious growth plans,” says Philipp v. Hammerstein, Partner at Gimv in the Health & Care team in Munich.
The new investment is already Gimv’s fifth acquisition in the German-speaking healthcare market within the last four years. Gimv currently holds a total of 23 investments in companies in the healthcare and life sciences sector. With this acquisition, Gimv once again underlines its position as one of the most active European investors in the healthcare industry and its ambition to positively contribute to the United Nations goals; in this case “Health and Wellbeing”. The Gimv portfolio also includes several hospital and practice groups as well as medical technology and biotech companies.
Gimv is a European investment company with 40 years of experience in private equity. The company is listed on Euronext Brussels, currently manages around EUR 2.0 billion and currently invests in 55 portfolio companies, which together generate revenues of more than EUR 2.5 billion and employ 14,000 people. Gimv’s aspiration to make a positive value contribution to society is reflected, among other things, in the recently successfully launched Sustainable Bond.
Gimv identifies innovative, leading companies with high growth potential and supports them sustainably on their way to market leadership. Each of the four investment platforms Consumer, Health & Care, Smart Industries and Sustainable Cities is managed by a dedicated and competent team, each based in Gimv’s home markets — Benelux, France and DACH — and supported by an extensive international network of experts.